Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 25;17(8):8762-72.
doi: 10.3390/molecules17088762.

Synthesis and cytotoxicity testing of new amido-substituted triazolopyrrolo[2,1-c][1,4]benzodiazepine (PBDT) derivatives

Affiliations

Synthesis and cytotoxicity testing of new amido-substituted triazolopyrrolo[2,1-c][1,4]benzodiazepine (PBDT) derivatives

Kumaraswamy Sorra et al. Molecules. .

Abstract

A series of amido-substituted triazolopyrrolo[2,1-c][1,4]benzodiazepine (PBDT) derivatives was synthesized from isatoic anhydride, and their cytotoxicity against the MRC-5 and Mahlavu cell lines was evaluated. The results suggest that compound PBDT-7i with the meta-trifluoromethylbenzoyl substituent can selectively inhibit the growth of Mahlavu cells and has low toxicity towards MRC-5 cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Members of the benzodiazepine family.
Scheme 1
Scheme 1
Synthesis of triazolo-fused PBD and derivatives.
Figure 2
Figure 2
PBDT-7a–k induced the death of Mahlavu cells. The concentration-dependent effects of PBDT-7a–k on human hepatocellular carcinoma cells. Mahlavu cells were treated with PBDT-7 series compounds for 48 h, and survival was assessed using a CCK-8 assay (mean ± SEM, n = 6).
Figure 3
Figure 3
The cytotoxicity assay of PBDT-7a–k against MRC-5 cells. The concentration-dependent effect of PBDT-7a–k on normal human fibroblast cells. MRC-5 cells were treated with PBDT-7 series compounds for 48 h, and survival was assessed using a CCK-8 assay (mean ± SEM, n = 6).

Similar articles

Cited by

References

    1. McGlynn K.A., Tsao L., Hsing A.W., Devesa S.S., Fraumeni J.F., Jr. International trends and patterns of primary liver cancer. Int. J. Cancer. 2001;94:290–296. doi: 10.1002/ijc.1456. - DOI - PubMed
    1. Li L.Y., Dai H.Y., Yeh F.L., Kan S.F., Lang J., Hsu J.L., Jeng L.B., Chen Y.H., Sher Y.P., Lin W.C., Hung M.C. Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene. 2011;30:1773–1783. doi: 10.1038/onc.2010.558. - DOI - PubMed
    1. McCall W.V. A psychiatric perspective on insomnia. J. Clin. Psychitr. 2001;62:27–32. - PubMed
    1. Hsu M.C., Schutt A.D., Holly M., Slice L.W., Sherman M.I., Richman D.D., Potash M.J., Volsky D.J. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science. 1991;254:1799–1802. doi: 10.1126/science.1763331. - DOI - PubMed
    1. Micale N., Vairagoundar R., Yakovlev A.G., Kozikowski A.P. Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. J. Med. Chem. 2004;47:6455–6458. doi: 10.1021/jm049248f. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources